This study will evaluate the safety and efficacy of MK-4280 in combination with pembrolizumab
(MK-3475) in participants with hematological malignancies:
classical Hodgkin lymphoma (cHL)
diffuse large B-cell lymphoma (DLBCL)
indolent non-Hodgkin lymphoma (iNHL) The study will have 2 phases: a safety lead-in and
an efficacy expansion phase. The recommended Phase 2 dose (RPTD) will be determined in
the safety lead-in phase by evaluating dose-limiting toxicities.
Clinical Study Identifier
Merck Sharp & Dohme Corp.
Last Modified on
14 September 2020
How clear was the trial content above?
Adding a note
Select a piece of text and start making personal notes.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.